Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination drug **hyaluronic acid + amino acid** consists of **hyaluronic acid** (HA), a naturally occurring glycosaminoglycan known for its remarkable water-retention and tissue hydration properties, and selected **amino acids** (such as glycine and proline, often key precursors in collagen synthesis). This combination is used primarily for skin and wound treatments where HA acts to hydrate the extracellular matrix and stimulate CD44 receptor pathways—promoting cell proliferation, migration, and extracellular matrix (ECM) bioregeneration. Amino acids further enhance this effect by directly supporting the synthesis of collagen and elastin, thereby improving skin structure, elasticity, and wound healing. Clinical evidence supports its efficacy and safety for management of skin damage from dehydration, UV exposure, aging, and various types of wounds (acute, chronic, diabetic, venous stasis ulcers, and post-surgical wounds)[1][2][4]. The medication is available in different forms, including injectable solutions (mesotherapy), powders, gels, and creams[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + amino acid.